{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-124393","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.187874+00:00","generated_at":"2026-05-15T08:59:42.225522+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atossa Therapeutics Reports Q4 and FY2025 Results, Highlights (Z)-Endoxifen Progress in DMD","bullets":["Atossa reported FY2025 operating expenses of $37.1M, up from $27.6M; R&D expenses increased 50% to $21.2M.","Received FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy.","Added Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. as Medical Directors for breast oncology and rare diseases.","Interest income decreased to $2.4M from $4.1M; no impairment charge in 2025 vs $1.7M in 2024.","(Z)-endoxifen being evaluated in multiple settings including breast cancer and rare diseases DMD and MAS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-124393","json":"https://secwatch.observer/filing/0001193125-26-124393.json","markdown":"https://secwatch.observer/filing/0001193125-26-124393.md","text":"https://secwatch.observer/filing/0001193125-26-124393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526124393/0001193125-26-124393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526124393/atos-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T08:59:42.225522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}